Therapeutic Potential of Senolytics in Cardiovascular Disease

Ageing is the biggest risk factor for impaired cardiovascular health, with cardiovascular disease being the leading cause of death in 40% of individuals over 65 years old. Ageing is associated with both an increased prevalence of cardiovascular disease including heart failure, coronary artery diseas...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 2022-02, Vol.36 (1), p.187-196
Main Authors: Dookun, Emily, Passos, João F., Arthur, Helen M., Richardson, Gavin D.
Format: Article
Language:English
Subjects:
Aged
Aging
Animals
Apoptosis
Apoptosis - drug effects
Atherosclerosis
Cardiology
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - physiopathology
Cellular Senescence - drug effects
Congestive heart failure
Coronary artery
Coronary artery disease
Disease Progression
Health risks
Humans
Inflammation
Invited Review
Invited Review Article
Medicine
Medicine & Public Health
Myocardial infarction
Pathophysiology
Phenotypes
Prognosis
Risk analysis
Risk Factors
Senescence
Senescence-Associated Secretory Phenotype - physiology
Senotherapeutics - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ageing is the biggest risk factor for impaired cardiovascular health, with cardiovascular disease being the leading cause of death in 40% of individuals over 65 years old. Ageing is associated with both an increased prevalence of cardiovascular disease including heart failure, coronary artery disease, and myocardial infarction. Furthermore, ageing is associated with a poorer prognosis to these diseases. Genetic models allowing the elimination of senescent cells revealed that an accumulation of senescence contributes to the pathophysiology of cardiovascular ageing and promotes the progression of cardiovascular disease through the expression of a proinflammatory and profibrotic senescence-associated secretory phenotype. These studies have resulted in an effort to identify pharmacological therapeutics that enable the specific elimination of senescent cells through apoptosis induction. These senescent cell apoptosis-inducing compounds are termed senolytics and their potential to ameliorate age-associated cardiovascular disease is the focus of this review.
ISSN:0920-3206
1573-7241
1573-7241
DOI:10.1007/s10557-020-07075-w